To date, the majority of in vivo work has been conducted in rodent models of diabetes, with rat and mouse models of STZ-induced type 1 diabetes and the db/db mouse model of type 2 diabetes used to evaluate both systemic and topical delivery of M1R antagonists [124,130]. This evidence concerns the gene CHRM1 and type 2 diabetes mellitus.